



# The EUCAST disk diffusion method for anaerobic bacteria

Erika Matuschek, Ph D  
Head of EUCAST Development Laboratory (EDL)

# AST of anaerobic bacteria

- Agar dilution is the reference method for AST of anaerobic bacteria (EUCAST and CLSI)
- **EUCAST methods**
  - Agar dilution on FAA with 5% defibrinated horse blood (FAA-HB)
  - Disk diffusion on FAA-HB
- **CLSI methods**
  - Agar dilution on Brucella Blood Agar with hemin and vitamin K (BBA)
  - Broth microdilution i Brucella broth (*Bacteroides* spp. only)
  - No disk diffusion method

# Correlation between agar dilution MICs on FAA-HB and BBA

## Benzylpenicillin

212 isolates of various species

	Brucella																
	<0.008	0.016	0.03	0.06	0.125	0.25	0.5	1	2	4	8	16	32	64	128	256	≥512
FAA	<0.008	12	11	2													
	0.016	11	12	15	1												
	0.03	30	1	10	7												
	0.06	9	1	4	10	12											
	0.125				2	21	5										
	0.25					3	7	1									
	0.5							1	1								
	1								2	1	1						
	2								1	5	2						
	4									2	2	2					
	8									1	2	2					
	16									2		1					
	32										1		1				
	64											2					
	128												1				
	256													1			
	≥512																

Identical MICs

MICs 1 dilution higher or lower

Lower MICs on BBA for some *F. necrophorum*, probably due to poorer growth on BBA.

# Disk diffusion methodology

<b>Inoculum</b>	McF 1.0 (0.9-1.1)
<b>Medium</b>	Fastidious Anaerobe Agar with 5% mechanically defibrinated horse blood (FAA-HB)
<b>Incubation</b>	Anaerobic environment 35-37°C, 16-20 h
<b>Reading of zones</b>	Read zone diameters from the front of the plate See specific Reading Guide for anaerobic bacteria

- AST of bacteria**
- IVDR
- Media preparation
- MIC determination
- Disk diffusion methodology**
- Disk diffusion implementation
- Breakpoint tables
- Quality Control
- Strains with defined susceptibility
- Calibration and validation

[www.eucast.org](http://www.eucast.org)

- [Disk diffusion manual v 13.0 \(1 January, 2025\)](#)
- [Disk diffusion - Slide show v 13.0 \(1 January, 2025\)](#)
- [Disk diffusion - Reading guide v 11.0 \(1 January, 2025\)](#)
- [Anaerobic bacteria - disk diffusion methodology v 2.0 \(2 January 2023\). QC recommendations are now included in the general \[QC document\]\(#\).](#)
- [Anaerobic bacteria - disk diffusion reading guide v 2.0 \(2 January 2023\). Disk diffusion breakpoints for anaerobic bacteria are valid for FAA with 5% mechanically defibrinated horse blood as the only additive.](#)

# Important aspects of methodology

- Dry plates before inoculation
- *Bacteroides* spp. and *C. perfringens*
  - Remove excess fluid from the cotton swab before inoculation to avoid over-inoculation
- *Prevotella* spp., *F. necrophorum* and *C. acnes*
  - Do not remove excess fluid, and spread the inoculum evenly over the entire agar surface, ensuring that there are no gaps between streaks
- Limit the number of disks on each plate to allow good growth and to avoid overlapping of zones
- Follow the specific reading instructions

# Reading of zones

## Specific instructions




No zone


- Ignore any faint haze within the inhibition zone and read the most obvious zone. **Tilt the plate towards you to better define the obvious zone edge.**
- Ignore haemolysis and swarming and read inhibition of growth.
- Isolated colonies within the inhibition zone should be taken into account. **For clindamycin, it is particularly important to examine zones carefully for colonies growing within the zone.**

# Correlation between disk diffusion and agar dilution *Bacteroides* spp.


# Piperacillin-tazobactam




# **Meropenem**



# Clindamycin



# Metronidazole



# EUCAST Breakpoint Tables v 15.0, January 2025

## Anaerobic bacteria

Expert Rules and Expected Phenotypes

Guidance documents

For species not listed below, see EUCAST Guidance Document on how to test and interpret results when there are no breakpoints

### MIC determination (agar dilution)

**Medium:** Fastidious Anaerobe Agar + 5% defibrinated horse blood (FAA-HB)

**Inoculum:**  $10^5$  CFU/spot

**Incubation:** Anaerobic environment, 35–37°C, 42–48h

**Reading:** Unless otherwise stated, read MICs at the lowest concentration of the agent where a noticeable difference is seen in visible growth between the test and control plate.

**Quality control:** *Bacteroides fragilis* ATCC 25285 and *Clostridium perfringens* ATCC 13124.

For control of the inhibitor component of beta-lactam inhibitor combinations, see EUCAST QC Tables. See disk diffusion methodology for how to monitor the anaerobic atmosphere with *Clostridium perfringens* DSM 25589.

## EUCAST Clinical Breakpoint Tables v. 15.0, valid from 2025-01-01

For abbreviations and explanations of breakpoints, see the Notes sheet

### Disk diffusion (EUCAST standardised disk diffusion method)

**Medium:** Fastidious Anaerobe Agar + 5% defibrinated horse blood (FAA-HB). The plates should be dried prior to inoculation (at 20–25°C overnight or at 35°C, with the lid removed, for 15 min).

**Inoculum:** McFarland 1.0

**Incubation:** Anaerobic environment, 35–37°C, 18–24h

**Reading:** Unless otherwise stated, read zone edges as the point showing no growth viewed from the front of the plate with the lid removed and with reflected light. See pictures below and the EUCAST Reading Guide for disk diffusion of anaerobic bacteria for further information.

**Quality control:** *Bacteroides fragilis* ATCC 25285 and *Clostridium perfringens* ATCC 13124. For control of the inhibitor component of beta-lactam inhibitor combination disks, see EUCAST QC Tables.

*Clostridium perfringens* DSM 25589 with a metronidazole 5 µg disk to monitor the anaerobic atmosphere.

## *Bacteroides* spp.

Breakpoints for *Bacteroides* spp. are also valid for *Parabacteroides* spp. and for *Phocaeicola dorei/vulgatus* (previously named *Bacteroides dorei/vulgatus*).

Antimicrobial agent	MIC breakpoints (mg/L)			Disk content (µg)	Zone diameter breakpoints (mm)			Notes
	S ≤	R >	ATU		S ≥	R <	ATU	
Ampicillin-sulbactam	2 <sup>1</sup>	2 <sup>1</sup>		10-10	25	25		1. For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. 2. For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. 3. Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.
Amoxicillin-clavulanic acid	2 <sup>2</sup>	2 <sup>2</sup>		2-1	14	14		
Piperacillin-tazobactam <sup>3</sup>	2 <sup>4</sup>	2 <sup>4</sup>		30-6	24	24		
Ertapecnem	(2) <sup>5</sup>	(2) <sup>5</sup>		10	(23) <sup>A</sup>	(23) <sup>A</sup>		
Imipenem	1	1		10	29	29		4. For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
Meropenem	1	1		10	28	28		5/A. For information on how to use breakpoints in brackets, see <a href="https://www.eucast.org/eucastguidancedocuments/">https://www.eucast.org/eucastguidancedocuments/</a> .
Clindamycin	(4) <sup>6</sup>	(4) <sup>6</sup>		2	(10) <sup>A,B</sup>	(10) <sup>A,B</sup>		
Metronidazole	4	4		5	25	25		B. Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.

## *Prevotella* spp.

Antimicrobial agent	MIC breakpoints (mg/L)			Disk content (µg)	Zone diameter breakpoints (mm)			Notes
	S ≤	R >	ATU		S ≥	R <	ATU	
Benzylpenicillin	0.5 <sup>1</sup>	0.5 <sup>1</sup>		1 unit	20 <sup>A</sup>	20 <sup>A</sup>		1/A. Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents within breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
Ampicillin	0.5 <sup>1</sup>	0.5 <sup>1</sup>		2	25 <sup>A</sup>	25 <sup>A</sup>		
Ampicillin-sulbactam	Note <sup>1,2</sup>	Note <sup>1,2</sup>		10-10	33 <sup>A</sup>	33 <sup>A</sup>		2. At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the <i>in vitro</i> antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.
Amoxicillin	0.25 <sup>1</sup>	0.25 <sup>1</sup>			Note <sup>A,B</sup>	Note <sup>A,B</sup>		
Amoxicillin-clavulanic acid	Note <sup>1,2</sup>	Note <sup>1,2</sup>		2-1	24 <sup>A</sup>	24 <sup>A</sup>		
Piperacillin-tazobactam	Note <sup>1,2</sup>	Note <sup>1,2</sup>		30-6	26 <sup>A</sup>	26 <sup>A</sup>		
Ertapecnem	0.5 <sup>1</sup>	0.5 <sup>1</sup>		10	29 <sup>A</sup>	29 <sup>A</sup>		
Imipenem	0.125 <sup>1</sup>	0.125 <sup>1</sup>		10	35 <sup>A</sup>	35 <sup>A</sup>		
Meropenem	0.25 <sup>1</sup>	0.25 <sup>1</sup>		10	34 <sup>A</sup>	34 <sup>A</sup>		B. Susceptibility can be inferred from ampicillin.
Clindamycin	0.25	0.25		2	31 <sup>C</sup>	31 <sup>C</sup>		
Metronidazole	4	4		5	22	22		C. Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.

## *Fusobacterium necrophorum*

Antimicrobial agent	MIC breakpoints (mg/L)			Disk content (µg)	Zone diameter breakpoints (mm)			Notes
	S ≤	R >	ATU		S ≥	R <	ATU	
Benzylpenicillin	0.125 <sup>1</sup>	0.125 <sup>1</sup>		1 unit	25 <sup>A</sup>	25 <sup>A</sup>		1/A. Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
Ampicillin	0.5 <sup>1</sup>	0.5 <sup>1</sup>		2	27 <sup>A</sup>	27 <sup>A</sup>		2. For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
Ampicillin-sulbactam	0.5 <sup>1,2</sup>	0.5 <sup>1,2</sup>		10-10	33 <sup>A</sup>	33 <sup>A</sup>		3. For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
Amoxicillin	0.5 <sup>1</sup>	0.5 <sup>1</sup>			Note <sup>A,B</sup>	Note <sup>A,B</sup>		4. For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
Amoxicillin-clavulanic acid	0.5 <sup>1,3</sup>	0.5 <sup>1,3</sup>		2-1	23 <sup>A</sup>	23 <sup>A</sup>		B. Susceptibility can be inferred from ampicillin.
Piperacillin-tazobactam	0.5 <sup>1,4</sup>	0.5 <sup>1,4</sup>		30-6	32 <sup>A</sup>	32 <sup>A</sup>		C. Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
Ertapenem	0.06 <sup>1</sup>	0.06 <sup>1</sup>		10	35 <sup>A</sup>	35 <sup>A</sup>		
Imipenem	0.125 <sup>1</sup>	0.125 <sup>1</sup>		10	36 <sup>A</sup>	36 <sup>A</sup>		
Meropenem	0.03 <sup>1</sup>	0.03 <sup>1</sup>		10	35 <sup>A</sup>	35 <sup>A</sup>		
Clindamycin	0.25	0.25		2	30 <sup>C</sup>	30 <sup>C</sup>		
Metronidazole	0.5	0.5		5	30	30		

## *Clostridium perfringens*

Antimicrobial agent	MIC breakpoints (mg/L)			Disk content (µg)	Zone diameter breakpoints (mm)			Notes
	S ≤	R >	ATU		S ≥	R <	ATU	
Benzylpenicillin	0.5 <sup>1</sup>	0.5 <sup>1</sup>		1 unit	15 <sup>A</sup>	15 <sup>A</sup>		1/A. Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
Ampicillin	0.25 <sup>1</sup>	0.25 <sup>1</sup>		2	23 <sup>A</sup>	23 <sup>A</sup>		2. For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
Ampicillin-sulbactam	0.25 <sup>1,2</sup>	0.25 <sup>1,2</sup>		10-10	27 <sup>A</sup>	27 <sup>A</sup>		3. For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
Amoxicillin	0.25 <sup>1</sup>	0.25 <sup>1</sup>			Note <sup>A,B</sup>	Note <sup>A,B</sup>		4. For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
Amoxicillin-clavulanic acid	0.25 <sup>1,3</sup>	0.25 <sup>1,3</sup>		2-1	23 <sup>A</sup>	23 <sup>A</sup>		B. Susceptibility can be inferred from ampicillin.
Piperacillin-tazobactam	0.5 <sup>1,4</sup>	0.5 <sup>1,4</sup>		30-6	24 <sup>A</sup>	24 <sup>A</sup>		C. Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
Ertapenem	0.5 <sup>1</sup>	0.5 <sup>1</sup>		10	24 <sup>A</sup>	24 <sup>A</sup>		
Imipenem	0.5 <sup>1</sup>	0.5 <sup>1</sup>		10	25 <sup>A</sup>	25 <sup>A</sup>		
Meropenem	0.125 <sup>1</sup>	0.125 <sup>1</sup>		10	25 <sup>A</sup>	25 <sup>A</sup>		
Vancomycin	2	2		5	12	12		
Clindamycin	0.25	0.25		2	19 <sup>C</sup>	19 <sup>C</sup>		
Metronidazole	4	4		5	16	16		

## *Cutibacterium acnes*

Antimicrobial agent	MIC breakpoints (mg/L)			Disk content (µg)	Zone diameter breakpoints (mm)			Notes
	S ≤	R >	ATU		S ≥	R <	ATU	
Benzylpenicillin	0.06 <sup>1</sup>	0.06 <sup>1</sup>		1 unit	24 <sup>A</sup>	24 <sup>A</sup>		1/A. Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
Ampicillin	0.25 <sup>1</sup>	0.25 <sup>1</sup>		2	23 <sup>A</sup>	23 <sup>A</sup>		2. At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the <i>in vitro</i> antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.
Ampicillin-sulbactam	Note <sup>1,2</sup>	Note <sup>1,2</sup>		10-10	33 <sup>A</sup>	33 <sup>A</sup>		
Amoxicillin	0.25 <sup>1</sup>	0.25 <sup>1</sup>			Note <sup>A,B</sup>	Note <sup>A,B</sup>		
Amoxicillin-clavulanic acid	Note <sup>1,2</sup>	Note <sup>1,2</sup>		2-1	24 <sup>A</sup>	24 <sup>A</sup>		
Piperacillin-tazobactam	Note <sup>1,2</sup>	Note <sup>1,2</sup>		30-6	27 <sup>A</sup>	27 <sup>A</sup>		
Cefotaxime	NA	NA		5	26 <sup>A,C</sup>	26 <sup>A,C</sup>		
Ceftriaxone	0.06 <sup>1</sup>	0.06 <sup>1</sup>		30	33 <sup>A,C</sup>	33 <sup>A,C</sup>		
Ertapenem	0.25 <sup>1</sup>	0.25 <sup>1</sup>		10	28 <sup>A</sup>	28 <sup>A</sup>		
Imipenem	0.03 <sup>1</sup>	0.03 <sup>1</sup>		10	39 <sup>A</sup>	39 <sup>A</sup>		
Meropenem	0.125 <sup>1</sup>	0.125 <sup>1</sup>		10	28 <sup>A</sup>	28 <sup>A</sup>		
Vancomycin	2	2		5	22	22		
Clindamycin	0.25	0.25		2	26 <sup>D</sup>	26 <sup>D</sup>		
Linezolid	2	2		10	34	34		


Discrepancies between piperacillin-tazobactam, ampicillin-sulbactam and amoxicillin-clavulanic acid for  
*Bacteroides* spp.

# Methodology is important!


- The EUCAST breakpoints for anaerobic bacteria are based on agar dilution and disk diffusion on FAA-HB
  - Broth microdilution should not be used
  - Gradient tests have not been evaluated
    - Note that some gradient tests (e.g. ampicillin-sulbactam) only are available in 2:1 ratio and not with fixed concentration of the inhibitor as recommended by EUCAST
- For disk diffusion, perform QC to make sure that the materials used produce results in agreement with EUCAST recommendations

# Agar dilution MIC distributions


Ampicillin-sulbactam MIC  
*Bacteroides* spp., 66 isolates



Amoxicillin-clavulanic acid MIC  
*Bacteroides* spp., 66 isolates




Piperacillin-tazobactam MIC  
*Bacteroides* spp., 50 isolates




# MIC-zone diameter correlations


Ampicillin-sulbactam 10-10 µg vs. MIC  
*Bacteroides* spp., 65 isolates (130 correlates)




Piperacillin-tazobactam 30-6 µg vs. MIC  
*Bacteroides* spp., 53 isolates (106 correlates)



**Amoxicillin-clavulanic acid 2-1 µg vs. MIC  
*Bacteroides* spp., 65 isolates (130 correlates)**




***Bacteroides* spp.**  
**Ampicillin-sulbactam vs. piperacillin-tazobactam MIC (agar dilution)**



# ***Bacteroides* spp.**


### **Ampicillin-sulbactam vs. piperacillin-tazobactam (disk diffusion)**



***Bacteroides* spp.**  
**Ampicillin-sulbactam vs. amoxicillin-clavulanic acid MIC (agar dilution)**

		Amoxicillin-clavulanic acid MIC (mg/L)													
		0.06	0.125	0.25	0.5	1	2	4	8	16	32	64	128	256	>256
Ampicillin-sulbactam MIC (mg/L)	0.06	1													
	0.125		5												
	0.25		1	9			1								
	0.5			7	3										
	1				4		1								
	2				5	1									
	4					1									
	8					1		1			1				
	16								1		1				
	32								1		1		1		
	64									1					
	128														
	256											1			
	>256											1			

***Bacteroides* spp.**  
**Ampicillin-sulbactam vs. amoxicillin-clavulanic acid (disk diffusion)**



# EUCAST Breakpoint Tables v 15.0, January 2025

## Anaerobic bacteria

### Expert Rules and Expected Phenotypes

### Guidance documents

For species not listed below, see EUCAST Guidance Document on how to test and interpret results when there are no breakpoints

#### MIC determination (agar dilution)

**Medium:** Fastidious Anaerobe Agar + 5% defibrinated horse blood (FAA-HB)

**Inoculum:** 10<sup>5</sup> CFU/spot

**Incubation:** Anaerobic environment, 35-37°C, 42-48h

**Reading:** Unless otherwise stated, read MICs at the lowest concentration of the agent where a noticeable difference is seen in visible growth between the test and control plate.

**Quality control:** *Bacteroides fragilis* ATCC 25285 and *Clostridium perfringens* ATCC 13124.

For control of the inhibitor component of beta-lactam inhibitor combinations, see EUCAST QC Tables. See disk diffusion methodology for how to monitor the anaerobic atmosphere with *Clostridium perfringens* DSM 25589.

## EUCAST Clinical Breakpoint Tables v. 15.0, valid from 2025-01-01

For abbreviations and explanations of breakpoints, see the Notes sheet

#### Disk diffusion (EUCAST standardised disk diffusion method)

**Medium:** Fastidious Anaerobe Agar + 5% defibrinated horse blood (FAA-HB). The plates should be dried prior to inoculation (at 20-25°C overnight or at 35°C, with the lid removed, for 15 min).

**Inoculum:** McFarland 1.0

**Incubation:** Anaerobic environment, 35-37°C, 18±2h

**Reading:** Unless otherwise stated, read zone edges as the point showing no growth viewed from the front of the plate with the lid removed and with reflected light. See pictures below and the EUCAST Reading Guide for disk diffusion of anaerobic bacteria for further information.

**Quality control:** *Bacteroides fragilis* ATCC 25285 and *Clostridium perfringens* ATCC 13124. For control of the inhibitor component of beta-lactam inhibitor combination disks, see EUCAST QC Tables.

*Clostridium perfringens* DSM 25589 with a metronidazole 5 µg disk to monitor the anaerobic atmosphere.

## *Bacteroides* spp.

Breakpoints for *Bacteroides* spp. are also valid for *Parabacteroides* spp. and for *Phocaeicola dorei/vulgatus* (previously named *Bacteroides dorei/vulgatus*).

Antimicrobial agent	MIC breakpoints (mg/L)			Disk content (µg)	Zone diameter breakpoints (mm)			Notes
	S ≤	R >	ATU		S ≥	R <	ATU	
Ampicillin-sulbactam	2 <sup>1</sup>	2 <sup>1</sup>		10-10	25	25		1. For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. 2. For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
Amoxicillin-clavulanic acid	2 <sup>2</sup>	2 <sup>2</sup>		2-1	14	14		3. Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.
Piperacillin-tazobactam <sup>3</sup>	2 <sup>4</sup>	2 <sup>4</sup>		30-6	24	24		4. For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
Ertapenem	(2) <sup>5</sup>	(2) <sup>5</sup>		10	(23) <sup>A</sup>	(23) <sup>A</sup>		5/A. For information on how to use breakpoints in brackets, see <a href="https://www.eucast.org/eucastguidancedocuments/">https://www.eucast.org/eucastguidancedocuments/</a> .
Imipenem	1	1		10	29	29		
Meropenem	1	1		10	28	28		
Clindamycin	(4) <sup>5</sup>	(4) <sup>5</sup>		2	(10) <sup>A,B</sup>	(10) <sup>A,B</sup>		
Metronidazole	4	4		5	25	25		B. Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.

**3. Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.**

# EUCAST QC Tables v 15.0, January 2025

## *Bacteroides fragilis* ATCC 25285

(NCTC 9343, DSM 2151, CCUG 4856T)

Antimicrobial agent	MIC (mg/L)		Disk content (µg)	Inhibition zone diameter (mm)	
	Target <sup>1</sup>	Range <sup>2</sup>		Target <sup>1</sup>	Range <sup>2</sup>
Amoxicillin-clavulanic acid <sup>3,4</sup>	<b>0.125</b>	<b>0.06-0.25</b>	2-1	<b>26</b>	<b>23-29</b>
Ampicillin-sulbactam <sup>4,5</sup>	<b>0.25</b>	<b>0.125-0.5</b>	10-10	<b>31</b>	<b>28-34</b>
Clindamycin	<b>1</b>	<b>0.5-2</b>	2	<b>25</b>	<b>22-28</b>
Ertapenem	<b>0.125</b>	<b>0.06-0.25</b>	10	<b>36</b>	<b>33-39</b>
Imipenem	<b>0.06</b>	<b>0.03-0.125</b>	10	<b>41</b>	<b>38-44</b>
Meropenem	<b>0.06-0.125</b>	<b>0.03-0.25</b>	10	<b>35-36</b>	<b>32-39</b>
Metronidazole	<b>0.5</b>	<b>0.25-1</b>	5	<b>32-33</b>	<b>29-36</b>
Piperacillin-tazobactam <sup>4,6</sup>	<b>0.25</b>	<b>0.125-0.5</b>	30-6	<b>32</b>	<b>29-35</b>

## *Clostridium perfringens* ATCC 13124

(NCTC 8237, CIP 103409, DSM 756, CCUG 1795T, CECT 376 T)

Antimicrobial agent	MIC (mg/L)		Disk content (µg)	Inhibition zone diameter (mm)	
	Target <sup>1</sup>	Range <sup>2</sup>		Target <sup>1</sup>	Range <sup>2</sup>
Amoxicillin	<b>0.016-0.03</b>	<b>0.008-0.06</b>	-	-	-
Amoxicillin-clavulanic acid <sup>3,4</sup>	<b>0.016-0.03</b>	<b>0.008-0.06</b>	2-1	<b>31</b>	<b>28-34</b>
Ampicillin	<b>0.016-0.03</b>	<b>0.008-0.06</b>	2	<b>32</b>	<b>29-35</b>
Ampicillin-sulbactam <sup>4,5</sup>	<b>0.016-0.03</b>	<b>0.008-0.06</b>	10-10	<b>35</b>	<b>32-38</b>
Benzylpenicillin	<b>0.06</b>	<b>0.03-0.125</b>	1 unit	<b>25</b>	<b>22-28</b>
Cefotaxime	-	-	5	<b>30</b>	<b>27-33</b>
Ceftriaxone	IP	IP	30	<b>34</b>	<b>31-37</b>
Clindamycin	<b>0.06</b>	<b>0.03-0.125</b>	2	<b>23</b>	<b>20-26</b>
Ertapenem	IP	IP	10	<b>34</b>	<b>31-37</b>
Imipenem	IP	IP	10	<b>34</b>	<b>31-37</b>
Linezolid	<b>4</b>	<b>2-8</b>	10	<b>24</b>	<b>21-27</b>
Meropenem	<b>0.008</b>	<b>0.004-0.016</b>	10	<b>36</b>	<b>33-39</b>
Metronidazole	<b>2</b>	<b>1-4</b>	5	<b>23</b>	<b>20-26</b>
Piperacillin-tazobactam <sup>4,6</sup>	<b>0.03-0.06</b>	<b>0.016-0.125</b>	30-6	<b>32</b>	<b>29-35</b>
Vancomycin	<b>1</b>	<b>0.5-2</b>	5	<b>17</b>	<b>14-20</b>

# Development of breakpoints and disk diffusion criteria for additional species

- *Clostridium ramosum*
- *Clostridium innocuum*
- *Clostridium tertium*
- *Clostridium septicum*
- *Cutibacterium avidum*
- *Fusobacterium nucleatum*
- *Finegoldia magna*
- *Parvimonas micra*
- *Peptostreptococcus anaerobius*
- *Peptoniphilus* spp.

# Problems or questions?

[erika.matuschek@eucast.org](mailto:erika.matuschek@eucast.org)



**EUCAST**

EUROPEAN COMMITTEE  
ON ANTIMICROBIAL  
SUSCEPTIBILITY TESTING

European Society of Clinical Microbiology and Infectious Diseases